Exelixis Hits Blockbuster Status

Exelixis Hits Blockbuster Status

Source: 
Motley Fool
snippet: 

Sales of Exelixis' (NASDAQ: EXEL) cabozantinib franchise, which includes Cabometyx for kidney and liver cancers and Cometriq for thyroid cancer, broke $250 million globally in the second quarter, making the drug a blockbuster, typically defined as $1 billion in annual sales.